Doxazosin
Clinical data | |
---|---|
Pronunciation | /dɒkˈseɪzəsɪn/ dok-SAY-zə-sin OR /ˌdɒksəˈzoʊsɪn/ DOK-sə-ZOH-sin |
Trade names | Cardura, Carduran, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693045 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 65% |
Protein binding | 98% |
Metabolism | Liver |
Elimination half-life | 22 hours |
Identifiers | |
| |
JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Doxazosin, sold under the brand names Cardura among others, is a
Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain.
Doxazosin was patented in 1977 and came into medical use in 1988.
A 2021 study associated doxazosin with decelerated biological aging in humans and confirmed its causal role in longevity in
Medical uses
High blood pressure
Doxazosin is usually added to other antihypertensive therapy such as
Doxazosin is generally considered to be safe, well tolerated and effective as an add-on antihypertensive drug.[9]
Like other alpha-1 receptor antagonists, it has a role in the peri-operative management of pheochromocytoma.[10]
Benign prostatic hyperplasia
Doxazosin is considered to be effective in reducing urinary symptom scores and improving peak urinary flow in men with benign prostatic hypertrophy.[11]
History
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study stopped its arm of the trial looking at alpha blockers, because doxazosin was less effective than a simple diuretic, and because patients on doxazosin had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics.[12] Pfizer, aware of the results before publication, launched a marketing campaign in early 2000, and sales were largely unaffected, despite the dangers highlighted by the study.[13][14]
References
- ^ a b "Cardura- doxazosin mesylate tablet". DailyMed. Retrieved 18 June 2021.
- ^ a b c d e f "Doxazosin Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- ^ ISBN 9780857113382.
- ISBN 9783527607495.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Doxazosin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- PMID 35822021.
- S2CID 42056694.
- S2CID 31819062.
- S2CID 25504151.
- S2CID 26341029.
- PMID 12459039.
- ISBN 0007350740.
- PMC 1128917.